P186 Prevalence and management of anaemia in Greek patients with inflammatory bowel disease: a multicentre real-life cohort study
K. Karmiris MD- PhD1, K. Fotinogiannopoulou2, M. Velegraki1, E. Koureta3, G. Axiaris4, C. Kateri5, G. Kokkotis6, C. Kapizioni7, P. Markopoulos8, A. Katsoula9, A. Gklavas10, I. Papaconstantinou10, O. Giouleme9, E. Tsironi8, G. Michalopoulos7, G. Bamias6, V. Papadopoulos5, A. Kapsoritakis5, E. Zampeli4, S. Michopoulos4, P. Karatzas3, G. Papatheodoridis3, A. Theodoropoulou1, I.E. Koutroubakis2
1Department of Gastroenterology, Venizeleio General Hospital, Heraklion, Greece, 2Department of Gastroenterology, University Hospital Heraklion, Heraklion, Greece, 3Department of Gastroenterology, Medical School of National and Kapodistrian University -–General Hospital ‘Laiko’, Athens, Greece, 4Department of Gastroenterology, Alexandra General Hospital, Athens, Greece, 5Department of Gastroenterology, University Hospital Larissa, Larissa, Greece, 6Department of Gastroenterology, Sotiria Hospital, Athens, Greece, 7Department of Gastroenterology, Tzaneio General Hospital, Piraeus, Greece, 8Department of Gastroenterology, Metaxa General Hospital, Piraeus, Greece, 9Department of Gastroenterology, Hippokration General Hospital,Thessaloniki, Greece, 10Department of Surgery, Aretaieion University Hospital, Athens, Greece
Anaemia is a common extra intestinal manifestation of inflammatory bowel disease (IBD) that plays an important role in patients’ quality of life. The aim of our study was to evaluate the prevalence of anaemia and its current management in referral IBD centres in Greece.
We performed a retrospective analysis of demographic, clinical, laboratory and IBD-related treatment data as well as data concerning the type of anaemia and its treatment in IBD patients registered in 10 Greek tertiary referral centres. Consecutive patients (the last seen) having at least two follow-up visits with available to retrieve relevant laboratory results were included. Anaemia was defined by the World Health Organization criteria. Patients with co-morbidities related to anaemia were excluded.
A total of 751 IBD patients have been registered so far and their demographic and clinical characteristics are presented in Table 1. The point prevalence of anaemia at inclusion was 26.8 % (201 patients), whereas the overall prevalence of history of anaemia was 38.7% (291 patients). The prevalence of anaemia was numerically higher in CD (41.1 %,
|Male/female (%)||397/354 (52.9/47.1)|
|CD/UC (%)||453/298 (60.3/39.7)|
|Median age at IBD diagnosis (years, IQR)||33 (23–45)|
|Median disease duration at entry (years, IQR)||5 (2–11)|
|Active smokers (%)||248 (33.0)|
|History of IBD-related surgery (%)||88 (11.7)|
|Anemia at entry (%)||201 (26.8)|
|History of anaemia (%)||291 (38.7)|
|Anemia in CD/UC (%)||186/105 (41.1/35.2)|
|Immunosupressants at entry (%)||177 (23.6)|
|Biologics at entry (%)||378 (50.3)|
|Iron supplementation (%)||239 (82.3)|
|Oral/iv iron (%)||52/205 (17.9/70.4)|
The point prevalence of anaemia in Greek IBD patients is 26.8%. Almost half of the patients with anaemia present recurrent or persistent anaemia. The presence of anaemia is associated with active disease and lower quality of life. The vast majority of patients received iron supplementation mainly in the form of iv iron.